Novartis AG (NVS)
Novartis AG (NYSE: NVS, SIX: NOVN) is a global pharmaceutical company headquartered in Basel, Switzerland. It researches, develops, manufactures and markets innovative prescription medicines across areas including oncology, immunology, cardiovascular and renal diseases, neuroscience, and respiratory conditions. Its portfolio includes treatments for cancer, multiple sclerosis, cardiovascular diseases and rare conditions. Novartis focuses on innovative medicines, supported by research and development, clinical trials and global commercialization.
| Ticker | NVS |
|---|
| Company | Novartis AG |
|---|
| Exchange | NYSE |
|---|
| Headquarters | BASEL, V8 |
|---|
Income statement — period ending 2025-12-31
| AdjustedWeightedAverageShares | 1,955,000,000 shares |
|---|
| BasicEarningsLossPerShare | 7 USD/shares |
|---|
| CostOfSales | $13,699,000,000 |
|---|
| DilutedEarningsLossPerShare | 7 USD/shares |
|---|
| GrossProfit | $42,975,000,000 |
|---|
| InterestExpense | $1,144,000,000 |
|---|
| ProfitLoss | $13,967,000,000 |
|---|
| ProfitLossAttributableToOwnersOfParent | $13,984,000,000 |
|---|
| ProfitLossFromOperatingActivities | $17,644,000,000 |
|---|
| ResearchAndDevelopmentExpense | $11,200,000,000 |
|---|
| SellingGeneralAndAdministrativeExpense | $13,248,000,000 |
|---|
| WeightedAverageShares | 1,939,000,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro